404 related articles for article (PubMed ID: 23936022)
21. Kinsenoside prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis by regulating classical NF-κB pathways.
Hsiao HB; Lin H; Wu JB; Lin WC
Osteoporos Int; 2013 May; 24(5):1663-76. PubMed ID: 23143538
[TBL] [Abstract][Full Text] [Related]
22. Kirenol inhibits RANKL-induced osteoclastogenesis and prevents ovariectomized-induced osteoporosis via suppressing the Ca
Zou B; Zheng J; Deng W; Tan Y; Jie L; Qu Y; Yang Q; Ke M; Ding Z; Chen Y; Yu Q; Li X
Phytomedicine; 2021 Jan; 80():153377. PubMed ID: 33126167
[TBL] [Abstract][Full Text] [Related]
23. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
24. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
25. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
26. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
Han B; Geng H; Liu L; Wu Z; Wang Y
Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
[TBL] [Abstract][Full Text] [Related]
27. Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis.
Chen X; Zhi X; Cao L; Weng W; Pan P; Hu H; Liu C; Zhao Q; Zhou Q; Cui J; Su J
Cell Death Dis; 2017 Sep; 8(9):e3037. PubMed ID: 28880271
[TBL] [Abstract][Full Text] [Related]
28. Cumambrin A prevents OVX-induced osteoporosis
Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J
FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
30. Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.
Cao J; Wang S; Wei C; Lin H; Zhang C; Gao Y; Xu Z; Cheng Z; Sun WC; Wang HB
Int Immunopharmacol; 2021 Jan; 90():107137. PubMed ID: 33199235
[TBL] [Abstract][Full Text] [Related]
31. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
32. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
Lin X; Yuan G; Yang B; Xie C; Zhou Z; Liu Y; Liu Z; Wu Z; Akimoto Y; Li N; Xu R; Song F
Phytomedicine; 2024 Jul; 129():155559. PubMed ID: 38579642
[TBL] [Abstract][Full Text] [Related]
33. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
[TBL] [Abstract][Full Text] [Related]
34. Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways.
Liu T; Jiang L; Xiang Z; Li J; Zhang Y; Xiang T; Wang W; Li X; Jia Y; Huang X; Lu X; Xu H; Wang X; Sheng J
Biomed Pharmacother; 2022 Jul; 151():113140. PubMed ID: 35605290
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
Cao B; Dai X; Wang W
J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
[TBL] [Abstract][Full Text] [Related]
36. Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL-induced osteoclastogenesis.
Qian Z; Zhong Z; Ni S; Li D; Zhang F; Zhou Y; Kang Z; Qian J; Yu B
J Cell Mol Med; 2020 Sep; 24(17):10112-10127. PubMed ID: 32790170
[TBL] [Abstract][Full Text] [Related]
37. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
38. Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K-AKT-NFATc1 pathway.
Cui J; Li X; Wang S; Su Y; Chen X; Cao L; Zhi X; Qiu Z; Wang Y; Jiang H; Huang B; Ji F; Su J
J Cell Mol Med; 2020 Jun; 24(11):6149-6161. PubMed ID: 32347017
[TBL] [Abstract][Full Text] [Related]
39. Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways.
Sun Y; Liu Y; He W; Wang C; Tickner J; Kuek V; Zhou C; Wang H; Zou X; Hong Z; Yang F; Shao M; Chen L; Xu J
J Cell Physiol; 2019 Jul; 234(7):11792-11804. PubMed ID: 30515822
[TBL] [Abstract][Full Text] [Related]
40. Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss.
Liu C; Guan H; Cai C; Li F; Xiao J
Exp Cell Res; 2017 Mar; 352(2):293-303. PubMed ID: 28209487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
